Kevin Tang, a director and 10% owner of Boundless Bio (NASDAQ:BOLD), has increased his stake in the company through open-market purchases totaling $4,677, according to recent filings. The transactions took place over two dates in November 2026, adding to his already substantial indirect holdings.
On November 6, 2026, Tang acquired 1,700 shares of Boundless Bio common stock. These shares were purchased at weighted-average prices ranging from $2.39 to $2.40 per share. Subsequently, on November 10, 2026, he bought an additional 249 shares, all at a price of $2.40 per share.
Following these transactions, Tang's indirect beneficial ownership in Boundless Bio stands at 3,035,567 shares. This ownership is held through various entities, including Tang Capital Partners, LP, Tang Capital Partners International, LP, Tang Capital Partners III, Inc., and Tang Capital Partners IV, Inc. Tang serves as the sole manager, director, or Chief Executive Officer for the entities controlling these holdings and has a pecuniary interest in the shares.
The insider buying comes as BOLD shares trade at $2.45, up 94% over the past year, though an analysis suggests the stock remains undervalued at current levels. The article does not provide additional details on the company's financial performance or the factors behind Tang's decision to increase his stake.
Insider transactions are closely watched by market participants as they can provide insight into internal confidence and valuation perceptions. However, the article does not speculate on the implications of Tang's purchases beyond the reported facts.